Agios Pharmaceuticals (AGIO) Revenue (2012 - 2026)

Agios Pharmaceuticals has reported Revenue for 14 years, with the latest figure at $20.7 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 137.75% year-over-year to $20.7 million; the trailing twelve-month figure through Mar 2026 stood at $66.0 million (up 78.34% YoY), and the FY2025 full-year result was $54.0 million, up 48.03% from the prior year.
• Revenue for Q1 2026 stood at $20.7 million, up from $20.0 million in the prior quarter.
• The five-year high for Revenue was $20.7 million in Q1 2026, with the low at $832000.0 in Q1 2022.
• Historically, Revenue has averaged $9.0 million across 5 years, with a median of $8.2 million in 2024.
• Annual changes were most pronounced in 2023 — Revenue jumped 574.16% — and 2025, when it advanced 6.56%.
• Agios Pharmaceuticals' Revenue stood at $4.3 million in 2022, then soared by 64.8% to $7.1 million in 2023, then surged by 51.06% to $10.7 million in 2024, then jumped by 86.09% to $20.0 million in 2025, then increased by 3.9% to $20.7 million in 2026.
• The last three Revenue figures came in at $20.7 million (Q1 2026), $20.0 million (Q4 2025), and $12.9 million (Q3 2025), per Business Quant data.